MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)

• Status: Completed
• Trial end date: 2012-02-07
• Target enrollment: 0
• Participant gender: All

Summary

This study is being conducted to evaluate the efficacy of MK-0954A in essential hypertension participants who are not adequately controlled with losartan.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Losartan

Criteria

Inclusion criteria:

• Participant has a diagnosis of essential hypertension.

• Participant is not treated with antihypertensive medication and meets protocol-specified blood pressure criteria.

• Participant is treated with single antihypertensive medication, and meets protocol-specified blood pressure criteria.

• Participant is being treated with up to dual oral antihypertensive medications, and will be able to discontinue the prior antihypertensive medication.

• Participant has no clinically meaningful findings to be disqualified from the study at the discretion of the investigator.

Exclusion criteria:

• Regarding hypertension, participant is currently taking > 2 antihypertensive medications.

• Participant has a history of significant multiple and/or severe allergies to ingredients of Nu-lotan or Preminent and thiazide drug or related drug (i.e., sulfonamide-containing "chlortalidone" medicines)

• Participant is, at the time of signing informed consent, a user of recreational or illicit drugs or a recent history within the last year of drug or alcohol abuse or dependence.

• Participant is pregnant or breastfeeding or expecting to conceive or has a positive pregnancy test at the screening visit.

• Participant is currently participating or has participated in a study with an investigational compound (except losartan at any doses) or device within 30 days of signing informed consent.